請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23355
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳基旺(Ji-Wang Chern) | |
dc.contributor.author | Mei-Jing Chiou | en |
dc.contributor.author | 邱美菁 | zh_TW |
dc.date.accessioned | 2021-06-08T04:59:41Z | - |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-18 | |
dc.identifier.citation | 1. Falkai, P.; Wobrock, T.; Lieberman, J.; Glenthoj, B.; Gattaz, W. F.; Moller, H. J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005, 6, 132-91.
2. Saha, S.; Chant, D.; Welham, J.; McGrath, J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2, 413-433. 3. Siris, S. G. Suicide and schizophrenia. J. Psychopharm. 2001, 15, 127-35. 4. Auquier, P.; Lançon, C.; Rouillon, F.; Lader, M.; Holmes, C. Mortality in schizophrenia. Pharmacoepidemiol. Drug Saf. 2006, 15, 873-879. 5. Kay, S. R.; Fiszbein, A.; Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13, 261-76. 6. Sawa, A.; Snyder, S. H. Schizophrenia: diverse approaches to a complex disease. Science 2002, 296, 692-695. 7. Zawilska, J. B. Dopamine receptors—structure, characterization and function. Postepy Hig Med Dosw 2003, 57, 293-322. 8. Kim, J.-H.; Auerbach, J. M.; Rodriguez-Gomez, J. A.; Velasco, I.; Gavin, D.; Lumelsky, N.; Lee, S.-H.; Nguyen, J.; Sanchez-Pernaute, R.; Bankiewicz, K.; McKay, R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002, 418, 50-56. 9. Meltzer, H. Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21, S106-S115. 10. Protais, P.; Chagraoui, A.; Arbaoui, J.; Mocaër, E. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents. Eur. J. Pharmacol. 1994, 271, 167-177. 11. Miner, L. A.; Backstrom, J. R.; Sanders-Bush, E.; Sesack, S. R. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 2003, 116, 107-17. 12. Schmidt, C. J.; Fadayel, G. M. The selective 5-HT2A receptor antagonist, MDL 100907 increases dopamine efflux in the prefrontal cortex of the rat. Eur. J. Pharmacol. 1995, 273, 273-9. 13. Martin, P.; Waters, N.; Carlsson, A.; Carlsson, M. L. The apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neura.l Trans. 1997, 104, 561-564. 14. Prinssen, E. P.; Ellenbroek, B. A.; Cools, A. R. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur. J. Pharmacol. 1994, 262, 167-70. 15. Schumacher, J.; Schulze, T. G.; Wienker, T. F.; Rietschel, M.; Nothen, M. M. Pharmacogenetics of the clozapine response. Lancet 2000, 356, 506-7. 16. Naidu, P. S.; Kulkarni, S. K. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur. J. Pharmacol. 2001, 428, 81-86. 17. Herrick-Davis, K.; Grinde, E.; Teitler, M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther. 2000, 295, 226-32. 18. Stefan, M.; Travis, M.; Murray, R. An atlas of schizophrenia. Parthenon Pub. Group: Boca Raton, 2002. 19. Lombardino, J. G.; Lowe, J. A. The role of the medicinal chemist in drug discovery - then and now. Nat. Rev. Drug. Discov. 2004, 3, 853-862. 20. Miyamoto, S.; Duncan, G. E.; Marx, C. E.; Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10, 79-104. 21. Bagnall, A. M.; Jones, L.; Ginnelly, L.; Lewis, R.; Glanville, J.; Gilbody, S.; Davies, L.; Torgerson, D.; Kleijnen, J. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess Rep 2003, 7, 1-193. 22. Emsley, R. A. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr. Bull. 1999, 25, 721-9. 23. Kongsamut, S.; Kang, J.; Chen, X.-L.; Roehr, J.; Rampe, D. A comparison of the receptor binding and hERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 2002, 450, 37-41. 24. Fossa, A. A.; Wisialowski, T.; Wolfgang, E.; Wang, E.; Avery, M.; Raunig, D. L.; Fermini, B. Differential effect of hERG blocking agents on cardiac electrical alternans in the guinea pig. Eur. J. Pharmacol. 2004, 486, 209-221. 25. Dolder, C.; Nelson, M.; Deyo, Z. Paliperidone for schizophrenia. Am. J. Health Syst. Pharm. 2008, 65, 403-13. 26. Meltzer, H. Y.; Matsubara, S.; Lee, J. C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 1989, 25, 390-2. 27. Trachsel, D.; Nichols, D. E.; Kidd, S.; Hadorn, M.; Baumberger, F. 4-Aryl-substituted 2,5-dimethoxyphenethylamines: synthesis and serotonin 5-HT2A receptor affinities. Chem. Biodivers. 2009, 6, 692-704. 28. Dezi, C.; Brea, J.; Alvarado, M.; Raviña, E.; Masaguer, C. F.; Loza, M. I.; Sanz, F.; Pastor, M. Multistructure 3D-QSAR studies on a series of conformationally constrained butyrophenones docked into a new homology model of the 5-HT2A receptor. J. Med. Chem. 2007, 50, 3242-3255. 29. Chern, J. W.; Tao, P. L.; Yen, M. H.; Lu, G. Y.; Shiau, C. Y.; Lai, Y. J.; Chien, S. L.; Chan, C. H. Studies on quinazolines. 5. 2,3-dihydroimidazo[1,2-c] -quinazoline derivatives - a novel class of potent and selective alpha 1-adrenoceptor antagonists and antihypertensive agents. J. Med. Chem. 1993, 36, 2196-2207. 30. Strupczewski, J. T.; Allen, R. C.; Gardner, B. A.; Schmid, B. L.; Stache, U.; Glamkowski, E. J.; Jones, M. C.; Ellis, D. B.; Huger, F. P.; Dunn, R. W. Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)- 1,2-benzisoxazoles. J. Med. Chem. 1985, 28, 761-9. 31. Aranda, R.; Villalba, K.; Raviña, E.; Masaguer, C. F.; Brea, J.; Areias, F.; Domínguez, E.; Selent, J.; López, L.; Sanz, F.; Pastor, M.; Loza, M. a. I. Synthesis, binding affinity, and molecular docking analysis of new benzofuranone derivatives as potential antipsychotics. J. Med. Chem. 2008, 51, 6085-6094. 32. Hitchcock, S. A. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr. Opin. Chem. Biol. 2008, 12, 318-323. 33. Ozeki, Y.; Fujii, K.; Kurimoto, N.; Yamada, N.; Okawa, M.; Aoki, T.; Takahashi, J.; Ishida, N.; Horie, M.; Kunugi, H. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 401-405. 34. Thomas, D.; Karle, C. A.; Kiehn, J. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr. Pharm. Des. 2006, 12, 2271-83. 35. Taylor, E. C.; McKillop, A.; Warrener, R. N. Heterocyclic syntheses from o-aminonitriles—XXVII : A one-step synthesis of fused pyrimidinedithiones. Tetrahedron 1967, 23, 891-896. 36. Lu, K.-Y. Synthesis and pharmacological evaluation of fused tricyclic thieno [3, 2-e] pyrimidine and quinazoline derivatives. Master dissertation. National Defense Medical Center, Taipei, R O C, 1991. 37. Bodea, C.; Silberg, I. Recent advances in the chemistry of phenothiazines. Adv. Heterocycl. Chem. 1968, 9, 321-460. 38. Incremona, J. H.; Martin, J. C. N-bromosuccinimide mechanisms of allylic bromination and related reactions. J. Am. Chem. Soc. 1970, 92, 627-634. 39. Cacchi, S.; Fabrizi, G.; Goggiamani, A. Palladium-catalyzed hydroxycarbonylation of aryl and vinyl halides or triflates by acetic anhydride and formate anions. Org. Lett. 2003, 5, 4269-4272. 40. Hesse, S.; Perspicace, E.; Kirsch, G. Microwave-assisted synthesis of 2-aminothiophene-3-carboxylic acid derivatives, 3H-thieno[2,3-d]pyrimidin-4- one and 4-chlorothieno[2,3-d]pyrimidine. Tetrahedron Lett. 2007, 48, 5261-5264. 41. Fatemi, S. H.; Pearce, D. A.; Brooks, A. I.; Sidwell, R. W. Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. Synapse 2005, 57, 91-9. 42. Jentsch, J. D.; Roth, R. H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20, 201-25. 43. Segal, D. S.; Geyer, M. A.; Schuckit, M. A. Stimulant-induced psychosis: an evaluation of animal methods. Essays Neur. Neuropharmacol. 1981, 5, 95-129. 44. Gray, N. S.; Pilowsky, L. S.; Gray, J. A.; Kerwin, R. W. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr. Res. 1995, 17, 95-107. 45. Sams-Dodd, F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 1996, 7, 3-23. 46. Kerns, E. H. Drug-like properties: concepts, sturcture design and methods : from ADME to toxicity optimization. Academic Press: Salt Lake City, 2008. 47. Gillman, A. G.; Leffel, J. K., 2nd; Kosobud, A. E.; Timberlake, W. Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24- and 31-h intervals. Behav. Brain Res. 2009, 205, 102-14. 48. Gewald, K.; Jeschke, T.; Gruner, M. Zur Reaktion von 2-Aminothiophen-3- carbonitrilen mit Heterocumulenen. Journal für Praktische Chemie 1991, 333, 229-236. 49. Iwamura, H.; Murakami, S.; Koshimizu, K.; Matsubara, S. Quantitative structure-activity relationships in cytokinin agonistic and antagonistic pyrido[2,3-d]pyrimidine derivates: insights into receptor topology. J. Med. Chem. 1985, 28, 577-583. 50. Akula, M. R.; Kabalka, G. W. Synthesis of 7-[123I]iodotacrine: a potential SPECT agent to map acetylcholinesterase. J. Labelled Comp. Radiopharm. 1999, 42, 959-964. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23355 | - |
dc.description.abstract | 精神分裂症是當前最嚴重的精神疾病之一,好發於青少年晚期或成人初期。傳統上治療精神分裂症的藥物為典型抗精神病藥物,利用阻斷多巴胺第二型接受器達到抗精神病之作用,但是會引起錐體外症狀。後來發展出非典型抗精神病藥物,為血清素二A亞型接受器拮抗劑,並且對於多巴胺第二型接受器親和力低。本實驗室先前以酮色林為先驅化合物合成2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one化合物,為血清素第二A型接受器拮抗劑,本研究以化合物15為先導化合物,p-fluorobenzoyl側鏈以環封閉設計等效異構物benzisoxazole官能基,與2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one縮合。此系列化合物具有血清素二A亞型接受器拮抗劑活性,並且達subnanomolar等級,在動物實驗之前脈衝抑制反射測試也發現氯、甲基以及甲氧基修飾之化合物具有改善精神分裂症的效果。 | zh_TW |
dc.description.provenance | Made available in DSpace on 2021-06-08T04:59:41Z (GMT). No. of bitstreams: 1 ntu-99-R97423024-1.pdf: 1920982 bytes, checksum: 0265378d2975e80d1ccba5f2e924dfbd (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 目錄
第一章 緒論 1 1.1 精神分裂症 1 1.2 精神分裂症治療 3 第二章 實驗動機與合成構想 7 2.1實驗動機 7 2.2 合成構想 8 第三章 結果與討論 12 3.1喹唑啉類化合物的合成 12 3.2 生物活性試驗結果 17 3.3 動物模式測試 19 第四章 結論 26 第五章 實驗部分 27 5.1實驗儀器 27 5.2試藥與溶劑 27 5.3 合成步驟 28 5.4生物活性測試條件 59 5.5動物模式測試方法 63 第六章 參考文獻 66 | |
dc.language.iso | zh-TW | |
dc.title | 設計與合成2,3-二水合咪唑喹唑啉酮衍生物作為
血清素接受器2A亞型拮抗劑 | zh_TW |
dc.title | Design and Synthesis of 2,3-Dihydroimidazo[1,2-c]quinazolin-5(6H)-ones as 5-HT2A Receptor Antagonists | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王光昭(Kuang-Chao Wang),顧記華(Jih-Hwa Guh),陳香惠(Shiahuy Chen),忻凌偉(Ling-Wei Hsin),孔繁璐(Fan-Lu Kung) | |
dc.subject.keyword | 血清素接受器2A亞型, | zh_TW |
dc.subject.keyword | 5-HT2A Receptor, | en |
dc.relation.page | 71 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2010-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 1.88 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。